In this study, we have developed a model of a bispecific antibody (BS1) targeting two key cell surface receptors, IL-6Rα and IL-8RB, which were recently implicated in a synergistic pathway that drives tumor metastasis [12,28]. Here, CD177 is linked to neoplasm.